SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$11.3b

SciClone Pharmaceuticals (Holdings) Balance Sheet Health

Financial Health criteria checks 6/6

SciClone Pharmaceuticals (Holdings) has a total shareholder equity of CN¥3.3B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥4.0B and CN¥735.2M respectively. SciClone Pharmaceuticals (Holdings)'s EBIT is CN¥1.4B making its interest coverage ratio -110.5. It has cash and short-term investments of CN¥2.2B.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ratio-110.5x
CashCN¥2.22b
EquityCN¥3.27b
Total liabilitiesCN¥735.18m
Total assetsCN¥4.00b

Recent financial health updates

No updates

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Financial Position Analysis

Short Term Liabilities: 6600's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥698.2M).

Long Term Liabilities: 6600's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥36.9M).


Debt to Equity History and Analysis

Debt Level: 6600 is debt free.

Reducing Debt: 6600 had no debt 5 years ago.

Debt Coverage: 6600 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6600 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.